tiprankstipranks
Trending News
More News >

SSY Group’s Nimodipine Gains Approval for Market Entry

Story Highlights
SSY Group’s Nimodipine Gains Approval for Market Entry

Confident Investing Starts Here:

An update from SSY Group ( (HK:2005) ) is now available.

SSY Group Limited has announced that its product, Nimodipine, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing new opportunities for growth in the pharmaceutical sector.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of drugs. The company is involved in creating treatments for various medical conditions, including ischemic cerebrovascular disease and hypertension.

YTD Price Performance: -0.47%

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.25B

For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App